1. |
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice[J]. Nat Rev Immunol, 2020, 20(11): 651-668. DOI: 10.1038/s41577-020-0306-5.
|
2. |
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38. DOI: 10.1038/s41572-020-0160-6.
|
3. |
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2(10): 1346-1353. DOI: 10.1001/jamaoncol.2016.1051.
|
4. |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381(16): 1535-1546. DOI: 10.1056/NEJMoa1910836.
|
5. |
Gerdes LA, Held K, Beltrán E, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis[J]. Ann Neurol, 2016, 80(2): 294-300. DOI: 10.1002/ana.24715.
|
6. |
Narumi Y, Yoshida R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report[J]. BMC Cancer, 2018, 18(1): 95. DOI: 10.1186/s12885-018-3997-2.
|
7. |
Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives[J]. Nat Rev Neurol, 2017, 13(12): 755-763. DOI: 10.1038/nrneurol.2017.144.
|
8. |
Mukharesh L, Chwalisz BK. Neuro-ophthalmic complications of immune-checkpoint inhibitors[J]. Semin Ophthalmol, 2021, 36(4): 241-249. DOI: 10.1080/08820538.2021.1890796.
|
9. |
Francis JH, Jaben K, Santomasso BD, et al. Immune checkpoint inhibitor-associated optic neuritis[J]. Ophthalmology, 2020, 127(11): 1585-1589. DOI: 10.1016/j.ophtha.2020.05.003.
|
10. |
Nasralla S, Abboud H. Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events[J/OL]. Mult Scler Relat Disord, 2020, 46: 102451[2020-08-15]. https://pubmed.ncbi.nlm.nih.gov/32835902/. DOI: 10.1016/j.msard.2020.102451.
|
11. |
Khimani K, Patel SP, Whyte A, et al. Case report: neuromyelitis optica after treatment of uveal melanoma with Nivolumab and Ipilimumab[J/OL]. Front Oncol, 2022, 12: 806501[2022-03-23]. https://pubmed.ncbi.nlm.nih.gov/35402220/. DOI: 10.3389/fonc.2022.806501.
|
12. |
Teodorescu R, Liu H, Sadun AA. Pembrolizumab-associated optic neuritis with an unusual manifestation of monocular optic disc edema[J/OL]. J Neuroophthalmol, 2023, 2023: E1(2022-12-16)[2023-01-04]. https://pubmed.ncbi.nlm.nih.gov/36728538/. DOI:10.1097/wno.0000000000001798. [published online ahead of print.
|
13. |
Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma[J]. J Immunother Cancer, 2016, 4: 66. DOI: 10.1186/s40425-016-0170-9.
|
14. |
Berry EC, Mullany S, Quinlivan A, et al. Eosinophilic vasculitis and arteritic anterior ischemic optic neuropathy associated with anti-PD-L1 therapy[J]. J Immunother, 2022, 45(1): 51-55. DOI: 10.1097/cji.0000000000000394.
|
15. |
Ahluwalia A, Kohli AA. Photopsias in the setting of Nivolumab therapy[J/OL]. J Neuroophthalmol, 2021, 41(1): e25-e26[2021-03-01]. https://pubmed.ncbi.nlm.nih.gov/32108668/. DOI: 10.1097/wno.0000000000000909.
|
16. |
Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade[J]. J Neuroophthalmol, 2021, 41(4): 519-530. DOI: 10.1097/wno.0000000000001148.
|
17. |
Yu CW, Yau M, Mezey N, et al. Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review[J]. Eye Brain, 2020, 12: 139-167. DOI: 10.2147/eb.S277760.
|
18. |
Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab[J]. Indian J Ophthalmol, 2019, 67(12): 2075-2077. DOI: 10.4103/ijo.IJO_1161_19.
|
19. |
Kawakado K, Tamura T, Nakanishi M, et al. Retrobulbar optic neuritis induced by Pembrolizumab in a patient with lung adenocarcinoma[J]. Intern Med, 2021, 60(24): 3941-3945. DOI: 10.2169/internalmedicine.7425-21.
|
20. |
Weiss D, Cantré D, Zettl UK, et al. Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab[J]. J Neurol, 2022, 269(5): 2778-2780. DOI: 10.1007/s00415-021-10913-y.
|
21. |
Makri OE, Dimitrakopoulos FI, Tsapardoni F, et al. Isolated optic neuritis after Pembrolizumab administration for non-small-cell lung carcinoma[J]. Int J Neurosci, 2022, 132(7): 643-648. DOI: 10.1080/00207454.2020.1831489.
|
22. |
Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy[J]. J Neuroophthalmol, 2015, 35(2): 144-147. DOI: 10.1097/wno.0000000000000217.
|
23. |
Toosy AT, Mason DF, Miller DH. Optic neuritis[J]. Lancet Neurol, 2014, 13(1): 83-99. DOI: 10.1016/s1474-4422(13)70259-x.
|
24. |
Pucar D, Boustani AM, Bronen RA, et al. Superior pituitary border analysis in immunotherapy-induced hypophysitis[J]. Clin Nucl Med, 2018, 43(4): 284-286. DOI: 10.1097/rlu.0000000000001981.
|
25. |
Kartal Ö, Ataş E. Bilateral optic neuritis secondary to Nivolumab therapy: a case report[J]. Medicina (Kaunas), 2018, 54(5): 82. DOI: 10.3390/medicina54050082.
|
26. |
Marraffa F, Dybala A, Grassi S, et al. Retrobulbar optic neuritis secondary to Nivolumab therapy for metastatic melanoma in a 71-year-old patient affected by multiple sclerosis[J]. Ital J Dermatol Venerol, 2022, 157(5): 454-455. DOI: 10.23736/s2784-8671.22.07204-8.
|
27. |
Cohen DA, Bhatti MT, Pulido JS, et al. Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema[J]. Ophthalmology, 2020, 127(2): 221-229. DOI: 10.1016/j.ophtha.2019.09.012.
|
28. |
Oliveira MCB, de Brito MH, Simabukuro MM. Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature[J/OL]. Front Neurol, 2020, 11: 538695[2020-12-11]. https://pubmed.ncbi.nlm.nih.gov/33362680/. DOI: 10.3389/fneur.2020.538695.
|
29. |
Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management[J]. Surv Ophthalmol, 2013, 58(5): 430-458. DOI: 10.1016/j.survophthal.2012.09.001.
|
30. |
Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG[J]. Ann Neurol, 2003, 54(1): 38-50. DOI: 10.1002/ana.10587.
|
31. |
Damek DM. Paraneoplastic retinopathy/optic neuropathy[J]. Curr Treat Options Neurol, 2005, 7(1): 57-67. DOI: 10.1007/s11940-005-0007-1.
|
32. |
Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes[J/OL]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(4): e1014[2021-05-18]. https://pubmed.ncbi.nlm.nih.gov/34006622/. DOI: 10.1212/nxi.0000000000001014.
|
33. |
Song S, Chang D, Li H, et al. Association of optic nerve sheath lesion and brain or meningeal metastasis caused by lung cancer[J]. Thorac Cancer, 2022, 13(15): 2164-2169. DOI: 10.1111/1759-7714.14538.
|
34. |
Achrol AS, Rennert RC, Anders C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 5. DOI: 10.1038/s41572-018-0055-y.
|
35. |
中国中西医结合学会检验医学专业委员会. 流式细胞术检测脑脊液肿瘤细胞的专家共识[J]. 中华检验医学杂志, 2021, 44(8): 679-689. DOI: 10.3760/cma.j.cn114452-20200927-00747.Chinese Association of Integrated Traditional and Western Medicine Laboratory Medicine Professional Committee. Consensus of experts on the detection of tumor cells in cerebrospinal fluid by flow cytometry[J]. Chin J Lab Med, 2021, 44(8): 679-689. DOI: 10.3760/cma.j.cn114452-20200927-00747.
|
36. |
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(Suppl): S119-142. DOI: 10.1093/annonc/mdx225.
|
37. |
中国抗癌协会肿瘤支持治疗专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会. 免疫检查点抑制剂相关神经不良反应诊治中国专家共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(9): 935-941. DOI: 10.3760/cma.j.cn112152-20220213-00098.Professional Committee of Tumor Supportive Therapy of Chinese Anti-Cancer Association, Professional Committee of Tumor Clinical Chemotherapy of Chinese Anti-Cancer Association. Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)[J]. Chin J Oncol, 2022, 44(9): 935-941. DOI: 10.3760/cma.j.cn112152-20220213-00098.
|
38. |
Kumar P, Saini S, Prabhakar BS. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis[J]. Semin Cancer Biol, 2020, 64: 29-35. DOI: 10.1016/j.semcancer.2019.01.006.
|